Current evidence indicates that lymphangioleiomyomatosis (LAM) arises from TSC1/2 gene mutations driving constitutive activation of the mTOR signaling pathway, which promotes dysregulated proliferation of neoplastic LAM cells. The gene discussed is TSC1; the disease is lymphangioleiomyomatosis.